AP03

About Avalyn Pharmaceuticals

Avalyn Pharma is a private, clinical-stage biotech focused on transforming the treatment of rare lung diseases through localized inhaled drug delivery. Its pipeline features two Phase 2 assets, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), and a preclinical fixed-dose combination, AP03, aiming to improve upon the tolerability limitations of current oral therapies. Led by an experienced team with deep respiratory and corporate development expertise, the company has raised over $275 million from a syndicate of top-tier life science investors. Avalyn is positioned to address a significant unmet need in a market with established systemic therapies but substantial side-effect burdens.

Therapeutic Areas